Boston reinforces clinical evidence to support Taxus platform
This article was originally published in Clinica
With the drug-eluting stent (DES) market poised to become increasingly crowded, Boston Scientific has released a new round of clinical data that it hopes will help it retain its number one position in the industry.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.